Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome.

Thumbnail Image
View / Download39.79 KB

Date

2014-06

Authors

Journal Title

Journal ISSN

Volume Title

Repository Usage Stats

39
views
35
downloads

Citation Stats

Abstract

We report on 27 patients with Down syndrome (DS) and acute lymphoblastic leukemia (ALL) who received allogeneic hematopoietic cell transplantation (HCT) between 2000 and 2009. Seventy-eight percent of patients received myeloablative conditioning and 52% underwent transplantation in second remission. Disease-free survival (DFS) was 24% at a median of 3 years. Post-transplant leukemic relapse was more frequent than expected for children with DS-ALL (54%) than for non-DS ALL. These data suggest leukemic relapse rather than transplant toxicity is the most important cause of treatment failure. Advancements in leukemia control are especially needed for improvement in HCT outcomes for DS-ALL.

Type

Journal article

Department

Description

Provenance

Subjects

CIBMTR Pediatric Cancer Working Committee, Humans, Down Syndrome, Graft vs Host Disease, Genetic Predisposition to Disease, Recurrence, Tacrolimus, Cyclosporine, Antineoplastic Combined Chemotherapy Protocols, Immunosuppressive Agents, Myeloablative Agonists, Disease-Free Survival, Treatment Outcome, Transplantation Conditioning, Combined Modality Therapy, Salvage Therapy, Whole-Body Irradiation, Remission Induction, Bone Marrow Transplantation, Hematopoietic Stem Cell Transplantation, Registries, Retrospective Studies, Adolescent, Adult, Child, Child, Preschool, Infant, Living Donors, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Kaplan-Meier Estimate, Allografts

Citation

Permalink

https://hdl.handle.net/10161/24654

Published Version (Please cite this version)

10.1002/pbc.24918

Publication Info

Hitzler, Johann K, Wensheng He, John Doyle, Mitchell Cairo, Bruce M Camitta, Ka Wah Chan, Miguel A Diaz Perez, Christopher Fraser, et al. (2014). Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome. Pediatric blood & cancer, 61(6). pp. 1126–1128. 10.1002/pbc.24918 Retrieved from https://hdl.handle.net/10161/24654.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Collections

Scholarly Articles
Full item page

Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.